Aardvark Therapeutics, Inc.
AARD
$8.49
-$0.50-5.56%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -163.66% | -327.46% | -330.13% | -98.29% | -256.38% |
| Total Depreciation and Amortization | 650.00% | 150.00% | -68.06% | 234.62% | -108.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 101.59% | -10.16% | 36.12% | -71.01% | -67.53% |
| Change in Net Operating Assets | 273.83% | -638.87% | 17.44% | 69.62% | 611.11% |
| Cash from Operations | -133.55% | -420.00% | -568.43% | -149.53% | -173.43% |
| Capital Expenditure | 2.15% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 10,217.20% | -2,252,380.00% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 96.26% | -- | -- | -- | -- |
| Cash from Financing | -100.09% | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -100.64% | -1,500.77% | -1,685.12% | -145.80% | 5,201.07% |